Should I buy or sell Applied Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" APLT shares. View APLT analyst ratings or view top-rated stocks .

What is Applied Therapeutics' stock price target for 2024?

1 Wall Street analysts have issued 1-year target prices for Applied Therapeutics' shares. Their APLT share price targets range from $5.00 to $14.00. On average, they anticipate the company's stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 205.5% from the stock's current price. View analysts price targets for APLT or view top-rated stocks among Wall Street analysts .

How have APLT shares performed in 2023?

Applied Therapeutics' stock was trading at $0.76 at the beginning of 2023. Since then, APLT stock has increased by 309.2% and is now trading at $3.11. View the best growth stocks for 2023 here .

When is Applied Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our APLT earnings forecast .

How were Applied Therapeutics' earnings last quarter?

Applied Therapeutics, Inc. (NASDAQ:APLT) issued its earnings results on Thursday, November, 9th. The company reported ($0.47) earnings per share for the quarter.

What ETF holds Applied Therapeutics' stock ?

Simplify Propel Opportunities ETF holds 2,382,621 shares of APLT stock, representing 3.53% of its portfolio.

What other stocks do shareholders of Applied Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include Enterprise Products Partners (EPD) , Pfizer (PFE) , Advanced Micro Devices (AMD) , Energy Transfer (ET) , Micron Technology (MU) , NVIDIA (NVDA) , Verizon Communications (VZ) , AbbVie (ABBV) , Walt Disney (DIS) and RTX (RTX) .

When did Applied Therapeutics IPO?

(APLT) raised $60 million in an initial public offering (IPO) on the week of May 13th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank acted as the underwriters for the IPO and Baird was co-manager.

Who are Applied Therapeutics' major shareholders?

Applied Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (4.40%), Rock Springs Capital Management LP (1.05%), AIGH Capital Management LLC (1.03%), Schonfeld Strategic Advisors LLC (0.59%), EAM Investors LLC (0.62%) and Worth Venture Partners LLC (0.25%). Insiders that own company stock include Charles Silberstein , Chids Mahadevan, Real Estate Equitie Alexandria, Riccardo Perfetti , Shoshana Shendelman and Stacy J Kanter. View institutional ownership trends .

How do I buy shares of Applied Therapeutics?

Shares of APLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Positive News SentimentPositive News

Applied Therapeutics Stock Price, News & Analysis (NASDAQ:APLT)

$3.11

+0.44 (+16.48%)

(As of 12/8/2023 ET)

Compare

Today's Range: $2.57
▼
$3.37
50-Day Range: $1.84
▼
$3.11
52-Week Range: $0.70
▼
$3.37

Volume: 3.82 million shs
Average Volume: 993,316 shs
Market Capitalization: $240.19 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.50

Applied Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 205.5% Upside
$9.50 Price Target
Short Interest: Healthy
2.56% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.88
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$967,043 Sold Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.62 out of 5 stars

Medical Sector

101st out of 933 stocks

Pharmaceutical Preparations Industry

31st out of 432 stocks

3.5

Analyst's Opinion

Consensus Rating
Applied Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.50, Applied Therapeutics has a forecasted upside of 205.5% from its current price of $3.11.
Amount of Analyst Coverage
Applied Therapeutics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.56% of the outstanding shares of Applied Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Applied Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Applied Therapeutics has recently increased by 2.59%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Applied Therapeutics does not currently pay a dividend.
Dividend Growth
Applied Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Applied Therapeutics has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Applied Therapeutics is -0.88.

3.9

News and Social Media Coverage

News Sentiment
Applied Therapeutics has a news sentiment score of 2.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Applied Therapeutics this week, compared to 0 articles on an average week.
Search Interest
Only 3 people have searched for APLT on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.
MarketBeat Follows
4 people have added Applied Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Applied Therapeutics insiders have sold 1,378.66% more of their company's stock than they have bought. Specifically, they have bought $65,400.00 in company stock and sold $967,043.00 in company stock.
Percentage Held by Insiders
19.10% of the stock of Applied Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
71.83% of the stock of Applied Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Applied Therapeutics is -2.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Applied Therapeutics is -2.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Applied Therapeutics has a P/B Ratio of 38.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Applied Therapeutics Stock (NASDAQ:APLT)

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target central nervous system rare disease and diabetic complications in the United States. Its lead product candidate is AT-007 that has completed phase III for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

APLT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

APLT Stock News Headlines

November 9, 2023 | msn.com

Applied Therapeutics GAAP EPS of -$0.47 misses by $0.21

November 9, 2023 | benzinga.com

Applied Therapeutics: Q3 Earnings Insights

December 10, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 9, 2023 | finance.yahoo.com

Applied Therapeutics Reports Third Quarter 2023 Financial Results

November 9, 2023 | finance.yahoo.com

Applied Therapeutics Inc (APLT) Reports Q3 2023 Financial Results Amidst Upcoming Clinical ...

November 5, 2023 | finance.yahoo.com

Applied Therapeutics, Inc. (NASDAQ:APLT) is definitely on the radar of institutional investors who own 38% of the company

November 3, 2023 | benzinga.com

Massive Insider Trade At Applied Therapeutics

November 2, 2023 | finance.yahoo.com

Applied Therapeutics to Present at the UBS Biopharma Conference 2023

December 10, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

November 1, 2023 | finance.yahoo.com

Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7

November 1, 2023 | morningstar.com

Applied Therapeutics Inc APLT

September 28, 2023 | finance.yahoo.com

Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual Meeting

September 6, 2023 | marketwatch.com

Applied Therapeutics Shares Rise 11% After Pre-NDA Meeting With FDA

September 6, 2023 | finance.yahoo.com

Applied Therapeutics Announces Successful Pre-NDA Meeting with the FDA and Confirms Plans to Submit NDA for Govorestat (AT-007) for Treatment of Classic Galactosemia to FDA in Q4 2023

August 17, 2023 | msn.com

Applied Therapeutics: Buy For Upcoming Pre-NDA Meeting (I Expect A Positive Outcome)

August 11, 2023 | seekingalpha.com

Applied Therapeutics GAAP EPS of -$0.37

August 10, 2023 | finance.yahoo.com

Applied Therapeutics Reports Second Quarter 2023 Financial Results

August 8, 2023 | fool.com

Applied Therapeutics (NASDAQ: APLT)

June 22, 2023 | finance.yahoo.com

Applied Therapeutics to Present Baseline Data on the Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes Association

June 17, 2023 | finance.yahoo.com

APLT - Applied Therapeutics, Inc.

June 15, 2023 | finance.yahoo.com

Applied Therapeutics to Present Data on AT-007 (Govorestat) Treatment in SORD Deficiency at the 2023 Annual Meeting of the Peripheral Nerve Society

May 25, 2023 | msn.com

Applied Therapeutics govorestat gets orphan drug tag in EU for muscle disorder

May 25, 2023 | finance.yahoo.com

Govorestat (AT-007) Receives Orphan Medicinal Product Designation from the EMA for Treatment of SORD Deficiency

May 11, 2023 | finance.yahoo.com

Applied Therapeutics Reports First Quarter 2023 Financial Results

May 5, 2023 | markets.businessinsider.com

7 Hot Growth Stocks Poised to Triple in 2023

April 25, 2023 | msn.com

Baird Maintains Applied Therapeutics (APLT) Outperform Recommendation

April 24, 2023 | msn.com

Applied Therapeutics' Investigational Drug Shows Clinical Benefit In Rare Metabolic Disorder, Chalks Out FDA Submission Plans

See More Headlines

Receive APLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/09/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/28/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:APLT
CUSIP: N/A
CIK: 1697532
Web: www.appliedtherapeutics.com
Phone: (212) 220-9226
Fax: N/A
Employees: 22
Year Founded: 2017

Price Target and Rating

Average Stock Price Target: $9.50
High Stock Price Target: $14.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +205.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.18)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-82,510,000.00
Net Margins: N/A
Pretax Margin: -905.38%
Return on Equity: -5,544.59%
Return on Assets: -245.57%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.80
Quick Ratio: 0.80

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.08 per share
Price / Book: 38.88

Miscellaneous

Outstanding Shares: 77,230,000
Free Float: 62,478,000
Market Cap: $240.19 million
Optionable: Not Optionable
Beta: 1.42

Social Links

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Dr. Shoshana Shendelman Ph.D. (Age 44)
Chair of the Board of Directors, Founder, President, CEO & Secretary
Comp: $813.47k
Dr. Riccardo Perfetti M.D. (Age 63)
Ph.D., Chief Medical Officer
Comp: $858k
Mr. Adam Hansard (Age 47)
Chief Commercial Officer
Comp: $742.66k
Ms. Catherine Thorpe (Age 60)
Interim Principal Financial Officer & Chief Accounting Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

APLT Stock Analysis - Frequently Asked Questions

Should I buy or sell Applied Therapeutics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" APLT shares.
View APLT analyst ratings or view top-rated stocks.
What is Applied Therapeutics' stock price target for 2024?: 1 Wall Street analysts have issued 1-year target prices for Applied Therapeutics' shares. Their APLT share price targets range from $5.00 to $14.00. On average, they anticipate the company's stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 205.5% from the stock's current price.
View analysts price targets for APLT or view top-rated stocks among Wall Street analysts.
How have APLT shares performed in 2023?: Applied Therapeutics' stock was trading at $0.76 at the beginning of 2023. Since then, APLT stock has increased by 309.2% and is now trading at $3.11.
View the best growth stocks for 2023 here.
When is Applied Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our APLT earnings forecast.
How were Applied Therapeutics' earnings last quarter?: Applied Therapeutics, Inc. (NASDAQ:APLT) issued its earnings results on Thursday, November, 9th. The company reported ($0.47) earnings per share for the quarter.
What ETF holds Applied Therapeutics' stock ?: Simplify Propel Opportunities ETF holds 2,382,621 shares of APLT stock, representing 3.53% of its portfolio.

What other stocks do shareholders of Applied Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include Enterprise Products Partners (EPD), Pfizer (PFE), Advanced Micro Devices (AMD), Energy Transfer (ET), Micron Technology (MU), NVIDIA (NVDA), Verizon Communications (VZ), AbbVie (ABBV), Walt Disney (DIS) and RTX (RTX).
When did Applied Therapeutics IPO?: (APLT) raised $60 million in an initial public offering (IPO) on the week of May 13th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank acted as the underwriters for the IPO and Baird was co-manager.
Who are Applied Therapeutics' major shareholders?: Applied Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (4.40%), Rock Springs Capital Management LP (1.05%), AIGH Capital Management LLC (1.03%), Schonfeld Strategic Advisors LLC (0.59%), EAM Investors LLC (0.62%) and Worth Venture Partners LLC (0.25%). Insiders that own company stock include Charles Silberstein, Chids Mahadevan, Real Estate Equitie Alexandria, Riccardo Perfetti, Shoshana Shendelman and Stacy J Kanter.
View institutional ownership trends.
How do I buy shares of Applied Therapeutics?: Shares of APLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:APLT) was last updated on 12/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial